Summit Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Summit Therapeutics

30/10/2024 15:21

* Summit Therapeutics Inc  SMMT.OQ  reported a quarterly
adjusted
loss of 8 cents​​ per share for the quarter ended September 30. 
The mean expectation of three analysts for the quarter was for a
loss of 7 cents per share. Wall Street expected results to range
from -7 cents to -6 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Summit Therapeutics Inc's reported EPS for the quarter was
a
loss of 8 cents​.
    * The company reported a quarterly loss of $56.3 million.
    * Summit Therapeutics Inc shares had fallen by 0.3% this
quarter and gained 736.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Summit
Therapeutics Inc is $40.00 
This summary was machine generated from LSEG data October 30 at
03:21 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.07          -0.08          Missed
 Jun. 30 2024      -0.06          -0.09          Missed
 Mar. 31 2024      -0.06          -0.06          Met